Article Text

Download PDFPDF
Novel anti-inflammatory effect of statins: reduction of CD4+CD28null T lymphocyte frequency in patients with unstable angina
  1. S Brugaletta,
  2. L M Biasucci,
  3. M Pinnelli,
  4. G Biondi-Zoccai,
  5. G Di Giannuario,
  6. G Trotta,
  7. G Liuzzo,
  8. F Crea
  1. Department of Cardiology, Catholic University, Rome, Italy
  1. Correspondence to:
    Dr Salvatore Brugaletta
    Department of Cardiology, Largo A Gemelli 8, 00168 Rome, Italy; salvatore.brugaletta{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Statins, inhibitors of 3-hydroxy-3-methyl glutaryl coenzyme A reductase, are potent inhibitors of cholesterol biosynthesis and have greatly improved the management of ischaemic heart disease. Recent studies suggest that direct antithrombotic and anti-inflammatory effects associated with treatment with statins may at least partly account for the reduction of cardiovascular events. In particular, statins reduce high sensitive C reactive protein (hs-CRP), tumour necrosis factor α, and metalloproteinase 9 production.1 Recently it has been shown that statins can modify the balance of T helper subset 1 (Th 1) and 2 (Th 2) cells by inhibition of Th1 development and augmentation of Th2 development of CD4+ T cells.2 In the present observational retrospective study we observed a relation between statin use and frequency of an unusual Th1 subset of T lymphocytes, CD4+CD28null, which is often expanded in unstable angina.3



We studied 111 consecutive patients (mean (SD) age 64 (9) years; 32 women) admitted to our coronary care unit with Braunwald class IIIB unstable angina: 33 had been taking statins for at least four weeks plus standard anti-ischaemic treatment (group 1: mean age 62 (9) years; seven women); the remaining 78 patients were taking standard anti-ischaemic treatment but not statins before admission (group 2: mean (SD) age 65 (9) years; 25 women). Clinical features were recorded for both groups (table 1). All participants gave their informed consent. The ethics committee of the Catholic University of Rome approved the study.

View this table:
Table 1

 Demographic and …

View Full Text